Welcome to the Miller Lab at the Medical College of Wisconsin Cancer Center. Our lab is focused on understanding the causes of drug resistance in breast cancer and the discovery of new treatment strategies.
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.
Nicole A Traphagen, Gary N Schwartz, Steven Tau, Alyssa M Roberts, Amanda Jiang, Sarah R Hosford, Jonathan D Marotti, Abigail E Goen, Bianca A Romo, Anneka L Johnson, Emily-Claire K Duffy, Eugene Demidenko, Paul Heverly, Yaron Mosesson, Shannon M Soucy, Fred Kolling, Todd W Miller.
Clin Cancer Res. 2023 Sep 15;29(18):3717-3728. doi: 10.1158/1078-0432.CCR-23-0488.
Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer.
Meisam Bagheri, Min Kyung Lee, Kristen E Muller, Todd W Miller, Diwakar R Pattabiraman, Brock C Christensen.
bioRxiv. 2023 Jun 10:2023.06.09.544426. doi: 10.1101/2023.06.09.544426. Preprint.
Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer.
Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar, Jonathan D Marotti, Mary D Chamberlin, Bradley A Arrick, Grace Makari-Judson, Matthew P Goetz, Shannon M Soucy, Fred Kolling, Eugene Demidenko, Todd W Miller.
Clin Cancer Res. 2023 Aug 1;29(15):2767-2773. doi: 10.1158/1078-0432.CCR-23-0112.